Topic: antibiotic-resistant bacteria
The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.
Novo Holdings' REPAIR Impact Fund will support programs into phase 2 in light of the tough funding environment for anti-infectives.
Fetroja works by using a "unique method" to penetrate the bacteria's cell walls and attack microorganism strains growing increasingly resistant to antibiotics, Shionogi says.
Xenleta is the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.
While many Big Pharma companies have exited antibiotic R&D work, Merck is pressing along and this summer won FDA approval for Recarbrio to treat complicated urinary tract infections and complicated intra-abdominal infections.
Two research teams are proposing new methods for killing drug-resistant bacteria by taking advantage of structural weaknesses.
The deal is part of a broader push by Brii to use some of the $260 million it raised last year to bring new antibiotics to patients.
MIT biological engineers found a way to rapidly engineer bacteriophages to kill E. coli by mutating a protein that binds to the target cells.
The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.
LUCA Biologics will develop “live biotherapeutics” for various women’s health conditions, ranging from bacterial vaginosis to preterm birth and infertility.